BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2016

View Archived Issues

Tesaro initiates phase I study of TSR-022 for advanced solid tumors

Read More

New phase I trial explores use of lentivirus alpha-gal A transduced CD34+ cells in Fabry disease

Read More

NIAID-sponsored phase I trial of yellow fever vaccine begins

Read More

GSK reflects on milestones of second quarter 2016

Read More

Methanobactin reverses mitochondrial impairment and acute liver failure in model of Wilson disease

Read More

Ono seeks Japanese approval for Opdivo for head and neck cancer

Read More

SAMD9 mutations cause new form of syndromic adrenal hypoplasia

Read More

International partnership to tackle the threat posed by antimicrobial resistance

Read More

European orphan drug designation awarded to volanesorsen for familial partial lipodystrophy

Read More

FIOCRUZ patents antituberculosis agents

Read More

University of Illinois discloses antifungal compounds

Read More

Auspex Pharmaceuticals describes modulators of melatonin receptors

Read More

Hitgen reports HDAC6 inhibitors

Read More

FDA grants breakthrough therapy designation to AVXS-101 for spinal muscular atrophy

Read More

Phase I results for Abeta oligomer receptor antagonist CT-1812

Read More

First-in-human results on LY-3002813

Read More

FDA grants fast track designation for CLBS-03 for the treatment of recent onset type 1 diabetes

Read More

Pfenex grants Jazz Pharmaceuticals rights to early-stage hematology product candidates

Read More

Omeros receives scientific advice from EMA on phase III program for OMS-721

Read More

ProterixBio earns grant from MJFF

Read More

Pfizer reports promising topline results from OCTAVE Sustain trial of Xeljanz

Read More

Editas Medicine and Fondazione Telethon and Ospedale San Raffaele form collaboration

Read More

Western Oncolytics and Pfizer enter immuno-oncology research collaboration

Read More

New company Nodthera Limited to focus on inhibitors of NLRP3

Read More

Adaptimmune Therapeutics gains access to EMA's PRIME initiative for T-cell therapy

Read More

Janssen files for approval of darunavir/cobicistat combination tablets in Japan

Read More

Supplemental application filed for Somatuline in Japan for neuroendocrine tumors

Read More

Protagonist Therapeutics receives grant to develop hepcidin mimetics

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing